toripalimab
Selected indexed studies
- Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. (JAMA, 2023) [PMID:38015220]
- Toripalimab. (, 2006) [PMID:38051794]
- Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. (JAMA, 2024) [PMID:38227033]
_Worker-drafted node — pending editorial review._
Connections
toripalimab is a side effect of
Sources
- Toripalimab plus axitinib versus sunitinib as first-line treatment for advanced renal cell carcinoma: RENOTORCH, a randomized, open-label, phase III study. (2024) pubmed
- Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma: The JUPITER-02 Randomized Clinical Trial. (2023) pubmed
- Toripalimab. (2006) pubmed
- Perioperative Toripalimab Plus Chemotherapy for Patients With Resectable Non-Small Cell Lung Cancer: The Neotorch Randomized Clinical Trial. (2024) pubmed
- Toripalimab plus chemotherapy in treatment-naïve, advanced esophageal squamous cell carcinoma (JUPITER-06): A multi-center phase 3 trial. (2022) pubmed
- Toripalimab for the treatment of melanoma. (2020) pubmed
- Disitamab Vedotin plus Toripalimab in HER2-Expressing Advanced Urothelial Cancer. (2025) pubmed
- Toripalimab Plus Chemotherapy as a First-Line Therapy for Extensive-Stage Small Cell Lung Cancer: The Phase 3 EXTENTORCH Randomized Clinical Trial. (2025) pubmed
- Toripalimab Plus Chemotherapy for Patients With Treatment-Naive Advanced Non-Small-Cell Lung Cancer: A Multicenter Randomized Phase III Trial (CHOICE-01). (2023) pubmed
- Toripalimab: First Global Approval. (2019) pubmed